Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma

Liver International

Volumn 34, Issue 4, 2014, Pages 612-620

  Heng Jun, Gao ^a   Yao Jun, Zhang ^a   Min shan, Che ^a   Mei Xian, Chen ^a   Jun Ting, Huang ^a   Li, Xu ^a   Lau, Wan Y ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BCLC B stage; Hepatocellular carcinoma; Survival; Transarterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; AMINOTRANSFERASE;

ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ACUTE GASTRODUODENAL ULCERATION; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; BACTEREMIA; BLEEDING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPLICATION; ESOPHAGUS VARICES BLEEDING; FEMALE; FEVER; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; HYPERTRANSAMINASEMIA; LIFE TABLE METHOD; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PATIENT CARE; SURVIVAL RATE; TREATMENT RESPONSE; VERY ELDERLY;

BCLC B STAGE; HEPATOCELLULAR CARCINOMA; SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHINA; COHORT STUDIES; FEMALE; HEPATITIS B; HUMANS; LIFE TABLES; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84895790658     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12307     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
3. Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg 1995; 221: 291-8.
4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
5. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
6. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
7. Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 2010; 42(Suppl 3): S258-63.
8. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30: 3-16.
9. EASL-EORTC clinical practice guidelines. Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
10. Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18: 413-20.
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
12. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-16.
13. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006; 44: 723-31.
14. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
15. Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 2498-9.
16. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
18. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
19. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
20. Hino O, Kajino K. Hepatitis virus-related hepatocarcinogenesis. Intervirology 1994; 37: 133-5.
21. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012; 56(Suppl 1): S75-87.
22. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1178-82.
23. Kim KW, Bae SK, Lee OH, et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998; 58: 348-51.
24. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303: 1062-9.
25. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55: 1309-16.
26. Luo J, Peng ZW, Guo RP, et al. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Radiology 2011; 259: 286-95.